Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 3

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 16Genitourinary 15Dermatologic 4Tumor-Agnostic 3Plasma cell 3Lymphoid 3Head & Neck 3Thoracic 2Other hematologic neoplasm 2Gynecologic 2Gastrointestinal 2CNS 2Sarcoma 1Other solid neoplasm 1Myeloid 1Endocrine 1

Conditions

Multiple Myeloma 2Smoldering Multiple Myeloma 1Recurrence 1Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia 1Hodgkin Disease 1

Interventions

Dexamethasone 882Bortezomib 481Lenalidomide 467Cyclophosphamide 367Melphalan 276Calcium Dobesilate 265daratumumab 241pomalidomide 216carfilzomib 188fludarabine phosphate 141fludarabine 137Thalidomide 125Peripheral Blood Stem Cell Transplantation 120Filgrastim 115ixazomib 94Mycophenolic Acid 91Granulocyte Colony-Stimulating Factor 90Busulfan 89Whole-Body Irradiation 88dexamethasone acetate 87Tacrolimus 79dexamethasone 21-phosphate 74isatuximab 70Cyclosporine 68auricularum 67Prednisone 67elotuzumab 63belantamab mafodotin 60Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Absorptiometry, Photon × Plasma cell × Clear all
NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
34 enrolled 18 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

NCT03951220 2025-08-19

LOOMIS

Oxford University Hospitals NHS Trust

Completed
67 enrolled 24 charts
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Neoplasms, Plasma Cell

NCT00401011 2018-02-23

Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients

AEterna Zentaris

Phase 1/2 Completed
84 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡